STOP-JIA (Start Time Optimization of Biologic Therapy in Polyarticular JIA) Study
FAMILIES WORK WITH RESEARCHERS TO FIND THE BEST WAY TO TREAT POLYARTICULAR JIA
STOP-JIA is funded by the Patient Centered Outcomes Research Institute (PCORI).
This study compares the effectiveness of starting treatment with a non-biologic medication (such as methotrexate), a biologic medication (such as etanercept, adalimumab, and tocilizumab), or a combination of non-biologic and biologic medications for patients with polyarticular forms of Juvenile Idiopathic Arthritis (pJIA). These treatment options were standardized by CARRA pediatric rheumatologist members and published as the pJIA Consensus Treatment Plans (CTPs). The treatments are chosen through discussion between the physician, patient and family and patients are followed in the CARRA registry to see how they do.
WHO IS INVOLVED?
53 CARRA Registry sites are participating across the US and Canada.
The coordinating center is the Duke Clinical Research Institute (DCRI).
WHY THIS IS IMPORTANT
There are a number of effective biologic therapies approved for the treatment of pJIA, but we don’t know if using these treatments first line makes an important difference in how quickly the patients get better, how they do in the long-term, or is safer than starting a traditional non-biologic medicine such as methotrexate first, and only starting a biologic therapy if the traditional medicine doesn’t work.
Our patient partners are primary members of our study team, and help us improve how the study is conducted by providing both the patient and patient perspectives. We are using electronic questionnaires to assist patients in reporting their symptoms and, for younger children, to enable parents to report their child’s symptoms.
This is the largest study to compare initial versus delayed biologic therapy in pJIA and is the first large-scale comparative effectiveness study of the CARRA pJIA CTPs.